Search

Your search keyword '"Rendon, Ricardo"' showing total 887 results
Start Over Author "Rendon, Ricardo"
887 results on '"Rendon, Ricardo"'

2. Benefit of Neoadjuvant Cisplatin-based Chemotherapy for Invasive Bladder Cancer Patients Treated with Radiation-based Therapy in a Real-world Setting: An Inverse Probability Treatment Weighted Analysis

Author

Kool, Ronald, Dragomir, Alice, Kulkarni, Girish S., Marcq, Gautier, Breau, Rodney H., Kim, Michael, Busca, Ionut, Abdi, Hamidreza, Dawidek, Mark, Uy, Michael, Fervaha, Gagan, Cury, Fabio L., Alimohamed, Nimira, Izawa, Jonathan, Jeldres, Claudio, Rendon, Ricardo, Shayegan, Bobby, Siemens, Robert, Black, Peter C., and Kassouf, Wassim

Published
2024
Full Text
View/download PDF

4. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial

Author

Ilie, Gabriela, Rendon, Ricardo, Mason, Ross, MacDonald, Cody, Kucharczyk, Michael J., Patil, Nikhilesh, Bowes, David, Bailly, Greg, Bell, David, Lawen, Joseph, Ha, Michael, Wilke, Derek, Massaro, Peter, Zahavich, Jeffery, Kephart, George, and Rutledge, Robert David Harold

Published
2023
Full Text
View/download PDF

5. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

Author

Abdi, Ehtesham, Allan, Suzanne, Bastick, Patricia, Begbie, Stephen, Blum, Robert, Briscoe, Karen, Brungs, Daniel, Bydder, Sean, Chittajallu, Bala Renuka, Cronk, Michelle, Cuff, Katharine, Davis, Ian D, Dowling, Anthony, Frydenberg, Mark, George, Matthew, Horvath, Lisa, Hovey, Elizabeth, Joshua, Anthony, Karanth, Narayan, Kichenadasse, Ganessan, Krieger, Laurence, Marx, Gavin, Mathlum, Maitham, Nott, Louise, Otty, Zulfiquer, Parnis, Francis, Pook, David, Sandhu, Shahneen, Sewak, Sanjeev, Stevanovic, Amanda, Stockler, Martin, Suder, Aneta, Tan, Hsiang, Torres, Javier, Troon, Simon, Underhill, Craig, Weickhardt, Andrew, Zielinski, Robert, Abbas, Tahir, Anan, Ghadeer, Booth, Chris, Campbell, Holly, Chi, Kim, Chin, Joseph, Chouinard, Edmond, Donnelly, Bryan, Drachenberg, Darrel, Faghih, Amir, Finelli, Antonio, Hotte, Sebastien, Noonan, Krista, North, Scott, Rassouli, Mohammad, Reaume, Neil, Rendon, Ricardo, Saad, Fred, Sadikov, Evgeny, Vigneault, Eric, Zalewski, Pawel, McCaffrey, John, McDermott, Ray, Morris, Patrick, O'Connor, Miriam, Donnellan, Paul, O'Donnell, Dearbhaile, Edwards, Jim, Fong, Peter, Tan, Alvin, Chowdhury, Simon, Crabb, Simon, Khan, Omar, Khoo, Vincent, Macdonald, Graham, Payne, Heather, Robinson, Angus, Shamash, Jonathon, Staffurth, John, Thomas, Carys, Thomson, Alastair, Sweeney, Christopher J, Martin, Andrew J, Stockler, Martin R, Cheung, Leanna, Chi, Kim N, Horvath, Lisa G, Joshua, Anthony M, Lawrence, Nicola J, McJannett, Margaret, North, Scott A, Parulekar, Wendy, Pook, David W, Reaume, Martin Neil, Sandhu, Shahneen K, Tan, Thean Hsiang, Vera-Badillo, Francisco, Williams, Scott G, Winter, Diana, Yip, Sonia, Zhang, Alison Y, and Zielinski, Robert R

Published
2023
Full Text
View/download PDF

7. A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.

Author

Fleshner, Neil E., primary, Bernardino, Rui Miguel, additional, Lajkosz, Katherine, additional, Saad, Fred, additional, Izawa, Jonathan, additional, Drachenberg, Darrel, additional, Saranchuk, Jeff W., additional, Tanguay, Simon, additional, Rendon, Ricardo A., additional, Leveridge, Michael, additional, Shayegan, Bobby, additional, Fairey, Adrian, additional, Cockburn, Jessica Grace, additional, Berlin, Doron, additional, Hamilton, Robert James, additional, Sildva, Tiiu, additional, Breau, Rodney H., additional, Richard, Patrick O., additional, Klotz, Laurence, additional, and Joshua, Anthony M., additional

Published
2024
Full Text
View/download PDF

8. MP53-03 REAL-WORLD RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

Author

Kim, Sandra, primary, Ma, Josh, additional, Eigl, Bernie, additional, Alimohamed, Nimira, additional, Kulkarni, Girish, additional, Chung, Peter, additional, Graham, Jeffrey, additional, Breau, Rodney, additional, Ong, Michael, additional, Levesque, Eric, additional, Basappa, Naveen, additional, Rendon, Ricardo, additional, Castilloux, Jean, additional, Winquist, Eric, additional, Siemens, Robert, additional, Lattouf, Jean-Baptiste, additional, Mukherjee, Som, additional, Yokom, Daniel, additional, Kassouf, Wassim, additional, and Black, Peter, additional

Published
2024
Full Text
View/download PDF

9. PD61-07 THE COMPREHENSIVE 6-MONTH PROSTATE CANCER-PATIENT EMPOWERMENT PROGRAM (PC-PEP) IMPROVES URINARY FUNCTION AMONG MEN WITH PROSTATE CANCER: PRELIMINARY RESULTS OF a PHASE 4 PAN-CANADIAN AND INTERNATIONAL IMPLEMENTATION TRIAL

Author

Gillis, Charlie, primary, Ilie, Gabriela, additional, MacDonald, Cody, additional, Mason, Ross, additional, Rendon, Ricardo, additional, Patel, Nikhilesh, additional, Bowes, David, additional, Bailly, Greg, additional, Bell, David, additional, Wilke, Derek, additional, and Rutledge, Robert, additional

Published
2024
Full Text
View/download PDF

10. MP77-13 DOWNSTAGING OF PRIMARY VS. SECONDARY MUSCLE INVASIVE BLADDER CANCER AFTER CYSTECTOMY AND ITS ASSOCIATION WITH SURVIVAL

Author

Caterini, Jessica E., primary, Kassouf, Wassim, additional, Breau, Rodney H., additional, Fairey, Adrian, additional, Agnihotram, Ramana-Kumar, additional, Alimohamed, Nimira, additional, Nayak, Jasmir G., additional, Lattouf, Jean-Baptiste, additional, Lodde, Michele, additional, Rendon, Ricardo, additional, Black, Peter, additional, Kulkarni, Girish S., additional, Chung, Peter, additional, and Siemens, D. Robert, additional

Published
2024
Full Text
View/download PDF

11. MP36-13 ASSOCIATION BETWEEN THE SARCOMATOID STATUS AND PERCENTAGE OF SARCOMATOID ON THE CLINICAL OUTCOMES OF LOCALIZED RENAL CELL CARCINOMA POST NEPHRECTOMY

Author

Soytas, Mustafa, primary, Bou-Nehme Sawaya, Ghady, additional, Dragomir, Alice, additional, Hesswani, Charles, additional, Finelli, Antonio, additional, Wood, Lori, additional, Rendon, Ricardo, additional, Kapoor, Anil, additional, Lalani, Aly-Khan, additional, Heng, Daniel, additional, Bhindi, Bimal, additional, Basappa, Naveen, additional, Dean, Lucas, additional, So, Alan, additional, Drachtenberg, Darel, additional, Bjarnason, Georg, additional, Breau, Rodney, additional, Lavallee, Luke, additional, Baptiste, Jean, additional, Pouliot, Frederic, additional, and Tanguay, Simon, additional

Published
2024
Full Text
View/download PDF

12. PD30-05 DEVELOPMENT AND EXTERNAL VALIDATION OF AN ARTIFICIAL INTELLIGENCE-BASED TOOL FOR PROGRESSION RISK ASSESSMENT IN NON-MUSCLE INVASIVE BLADDER CANCER (PROGRXN-BCA)

Author

Kwong, Jethro C. C., primary, Al-Daqqaq, Zizo, additional, Chelliahpillai, Yashan, additional, Lee, Soomin, additional, Kim, Kellie, additional, Ringa, Maximiliano, additional, Ali, Amna, additional, Feifer, Andrew, additional, Wettstein, Marian S., additional, Kassouf, Wassim, additional, Black, Peter C., additional, Breau, Rodney H., additional, Lodde, Michele, additional, Fairey, Adrian, additional, Lattouf, Jean-Baptiste, additional, Jeldres, Claudio, additional, Rendon, Ricardo, additional, Alimohamed, Nimira, additional, Chung, Peter, additional, Fleshner, Neil E., additional, Finelli, Antonio, additional, Zlotta, Alexandre R., additional, Johnson, Alistair E. W., additional, and Kulkarni, Girish S., additional

Published
2024
Full Text
View/download PDF

13. Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers

Author

Dragomir, Alice, Nazha, Sara, Tanguay, Simon, Breau, Rodney H., Bhindi, Bimal, Rendon, Ricardo A., Kapoor, Anil, Hotte, Sebastien J., Basappa, Naveen, Fairey, Adrian, So, Alan I., Kollmannsberger, Christian, Finelli, Antonio, Hansen, Aaron, Canil, Christina, Heng, Daniel, Lattouf, Jean-Baptiste, Bjarnason, Georg, Power, Nicholas, Pouliot, Frédéric, and Wood, Lori A.

Published
2022
Full Text
View/download PDF

14. Effect of Simulation-based Training on Surgical Proficiency and Patient Outcomes: A Randomised Controlled Clinical and Educational Trial

Author

Baig, Umair, Aya, Haleema, Husnain Iqbal, Mohammed, Kum, Francesca, Bultitude, Matthew, Glass, Jonathan, Khan, Azhar, Makanjuola, Jonathan, McCabe, John E., Samsuddin, Azi, McIlhenny, Craig, Brewin, James, Kulkarni, Shashank, Khwaja, Sikandar, Islam, Waliul, Marsh, Howard, Bhat, Taher, Thomas, Benjamin, Cutress, Mark, Housami, Fadi, Nedas, Timothy, Bates, Timothy, Mukherjee, Rono, Graham, Stuart, Bordenave, Matthieu, Coker, Charles, Ahmed, Shwan, Symes, Andrew, Calvert, Robert, Lynch, Ciaran, Long, Ronan, Patterson, Jacob M., Rukin, Nicholas J., Khan, Shahid A., Dasgupta, Ranan, Brown, Stephen, Grey, Ben, Mahmalji, Waseem, Lam, Wayne, Scheitlin, Walter, Saelzler, Norbert, Fiedler, Marcel, Ishikawa, Shuhei, Sasaki, Yoshihiro, Sazawa, Ataru, Shinno, Yuichiro, Mochizuki, Tango, Peter Jessen, Jan, Steiner, Roland, Wendt-Nordahl, Gunnar, Atassi, Nabil, Kohns, Heiko, Cox, Ashley, Rendon, Ricardo, Lawen, Joseph, Bailly, Greg, Marsh, Trevor, Aydın, Abdullatif, Ahmed, Kamran, Abe, Takashige, Raison, Nicholas, Van Hemelrijck, Mieke, Garmo, Hans, Ahmed, Hashim U., Mukhtar, Furhan, Al-Jabir, Ahmed, Brunckhorst, Oliver, Shinohara, Nobuo, Zhu, Wei, Zeng, Guohua, Sfakianos, John P., Gupta, Mantu, Tewari, Ashutosh, Gözen, Ali Serdar, Rassweiler, Jens, Skolarikos, Andreas, Kunit, Thomas, Knoll, Thomas, Moltzahn, Felix, Thalmann, George N., Lantz Powers, Andrea G., Chew, Ben H., Sarica, Kemal, Shamim Khan, Muhammad, and Dasgupta, Prokar

Published
2022
Full Text
View/download PDF

15. Drug Interactions between Androgen Receptor Axis-Targeted Therapies and Antithrombotic Therapies in Prostate Cancer: Delphi Consensus.

Author

Leblanc, Kori, Edwards, Scott J., Dranitsaris, George, Leong, Darryl P., Carrier, Marc, Malone, Shawn, Rendon, Ricardo A., Bond, Alison M., Sitland, Troy D., Zalewski, Pawel, Wang, Michelle, and Emmenegger, Urban

Abstract

Simple Summary: Prostate cancer is most commonly diagnosed in males after the age of 55 years. These patients are also at risk for cardiovascular disease and venous thromboembolism requiring antithrombotic therapy. Prostate cancer treatments, such as androgen receptor axis-targeted therapies (ARATs, i.e., abiraterone acetate, apalutamide, darolutamide, and enzalutamide), may interact with common antithrombotic medications like warfarin, clopidogrel, and the direct oral anticoagulants. However, the data detailing the clinical outcomes of patients treated with these combinations are limited. We undertook a comprehensive review of the literature and modified Delphi process to enable development of an evidence-based consensus document for the co-prescribing of ARATs with antithrombotic medications. Our assessments relied heavily on pharmacokinetic data and extrapolation from drug interaction studies of similarly metabolized drugs, highlighting the need for more research into the clinical impact of drug interactions in prostate cancer patients. Nonetheless, we provide a practical framework to support clinicians in day-to-day therapeutic decision making. Background/Objectives: Abiraterone acetate, apalutamide, darolutamide, and enzalutamide, which make up the androgen receptor axis-targeted therapies (ARATs) drug class, are commonly used in the management of prostate cancer. Many patients on ARATs also receive oral antithrombotic therapy (i.e., anticoagulants or antiplatelets). The concomitant use of ARATs and antithrombotic therapies creates the potential for clinically relevant drug–drug interactions, but the literature regarding the actual consequences of these interactions, and guidance for co-prescribing, is limited. We assembled a multidisciplinary panel of experts and provided them with clinical information derived from a comprehensive literature review regarding the drug–drug interactions between ARATs and antithrombotic therapies. Methods: A three-stage modified electronic Delphi process was used to gather and consolidate opinions from the panel. Each stage consisted of up to three rounds of voting to achieve consensus on which ARAT/antithrombotic therapy drug pairs warrant attention, the possible clinical consequences of drug–drug interactions, and suggested actions for management. Results: The panel achieved consensus to avoid 11 ARAT/antithrombotic therapy drug pairs and modify therapy for eight pairs. Assessments relied heavily on pharmacokinetic data and extrapolation from drug–drug interaction studies of similarly metabolized drugs. Conclusions: This e-Delphi process highlights the need for further research into the clinical impact of ARAT/antithrombotic drug interactions. Nonetheless, the suggested actions aim to provide clinicians with a practical framework for therapeutic decision making. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice

Author

Chi, Kim N., primary, Yip, Steven M., additional, Bauman, Glenn, additional, Probst, Stephan, additional, Emmenegger, Urban, additional, Kollmannsberger, Christian K., additional, Martineau, Patrick, additional, Niazi, Tamim, additional, Pouliot, Frédéric, additional, Rendon, Ricardo, additional, Hotte, Sebastien J., additional, Laidley, David T., additional, and Saad, Fred, additional

Published
2024
Full Text
View/download PDF

18. Six-Month Prostate Cancer Empowerment Program (PC-PEP) Improves Urinary Function: A Randomized Trial

Author

Lawen, Tarek, primary, Ilie, Gabriela, additional, Mason, Ross, additional, Rendon, Ricardo, additional, Spooner, Jesse, additional, Champion, Emmi, additional, Davis, Jessica, additional, MacDonald, Cody, additional, Kucharczyk, Michael J., additional, Patil, Nikhilesh, additional, Bowes, David, additional, Bailly, Greg, additional, Bell, David, additional, Lawen, Joseph, additional, Wilke, Derek, additional, Kephart, George, additional, and Rutledge, Robert David Harold, additional

Published
2024
Full Text
View/download PDF

23. Six-month prostate cancer empowerment program (PC-PEP) improves urinary function : a randomized trial

Author

Lawen, Tarek, Ilie, Gabriela, Mason, Ross, Rendon, Ricardo, Spooner, Jesse, Champion, Emmi, Davis, Jessica, MacDonald, Cody, Kucharczyk, Michael J., Patil, Nikhilesh, Bowes, David, Bailly, Greg, Bell, David, Lawen, Joseph, Wilke, Derek, Kephart, George, Rutledge, Robert David Harold, Lawen, Tarek, Ilie, Gabriela, Mason, Ross, Rendon, Ricardo, Spooner, Jesse, Champion, Emmi, Davis, Jessica, MacDonald, Cody, Kucharczyk, Michael J., Patil, Nikhilesh, Bowes, David, Bailly, Greg, Bell, David, Lawen, Joseph, Wilke, Derek, Kephart, George, and Rutledge, Robert David Harold

Abstract

Purpose: This is a secondary analysis examining a six-month home-based Prostate Cancer-Patient Empowerment Program (PC-PEP) on patient-reported urinary, bowel, sexual, and hormonal function in men with curative prostate cancer (PC) against standard of care. Methods: In a crossover clinical trial, 128 men scheduled for PC surgery (n = 62) or radiotherapy with/without hormones (n = 66) were randomized to PC-PEP (n = 66) or waitlist-control and received the standard of care for 6 months, and then PC-PEP to the end of the year. PC-PEP included daily emails with video instructions, aerobic and strength training, dietary guidance, stress management, and social support, with an initial PFMT nurse consultation. Over 6 months, participants in the PC-PEP received optional text alerts (up to three times daily) reminding them to follow the PFMT video program, encompassing relaxation, quick-twitch, and endurance exercises; compliance was assessed weekly. Participants completed baseline, 6, and 12-month International Prostate Symptom Score (IPSS) and Expanded Prostate Cancer Index Composite (EPIC) questionnaires. Results: At 6 months, men in the PC-PEP reported improved urinary bother (IPSS, p = 0.004), continence (EPIC, p < 0.001), and irritation/obstruction function (p = 0.008) compared to controls, with sustained urinary continence benefits at 12 months (p = 0.002). Surgery patients in the waitlist-control group had 3.5 (95% CI: 1.2, 10, p = 0.024) times and 2.3 (95% CI: 0.82, 6.7, p = 0.11) times higher odds of moderate to severe urinary problems compared to PC-PEP at 6 and 12 months, respectively. Conclusions: PC-PEP significantly improves lower urinary tract symptoms, affirming its suitability for clinical integration alongside established mental health benefits in men with curative prostate cancer.

Published
2024
Full Text
View/download PDF

25. Mediating Effects of Self-Efficacy and Illness Perceptions on Mental Health in Men with Localized Prostate Cancer: A Secondary Analysis of the Prostate Cancer Patient Empowerment Program (PC-PEP) Randomized Controlled Trial.

Author

MacDonald, Cody, Ilie, Gabriela, Kephart, George, Rendon, Ricardo, Mason, Ross, Bailly, Greg, Bell, David, Patil, Nikhilesh, Bowes, David, Wilke, Derek, Kokorovic, Andrea, and Rutledge, Robert D. H.

Subjects
HEART physiology, SELF-efficacy, ATTITUDES toward illness, RESEARCH funding, SECONDARY analysis, PSYCHOLOGICAL distress, STRESS management, EVALUATION of human services programs, PROSTATE tumors, PSYCHOLOGICAL stress, CANCER patient psychology, WELL-being, RELAXATION for health, DIET
Abstract

Simple Summary: This study investigates how the Prostate Cancer Patient Empowerment Program (PC-PEP) helps men with prostate cancer by promoting patient empowerment and activation. This program encourages patients to engage actively in their care, fostering healthy living habits daily, over six months. Involving 128 patients, this research found that those participating in the PC-PEP experienced significant improvements in self-efficacy and emotional responses, leading to reduced psychological distress compared to those receiving standard care. These findings underscore the importance of integrating the PC-PEP into clinical practice to enhance mental health and patient care strategies. Understanding how interventions reduce psychological distress in patients with prostate cancer is crucial for improving patient care. This study examined the roles of self-efficacy, illness perceptions, and heart rhythm coherence in mediating the effects of the Prostate Cancer Patient Empowerment Program (PC-PEP) on psychological distress compared to standard care. In a randomized controlled trial, 128 patients were assigned to either the PC-PEP intervention or standard care. The PC-PEP, a six-month program emphasizing daily healthy living habits, included relaxation and stress management, diet, exercise, pelvic floor muscle exercises, and strategies to improve relationships and intimacy, with daily activities supported by online resources and live sessions. Participants in the intervention group showed significant improvements in self-efficacy and specific illness perceptions, such as personal control and emotional response, compared to the control group. These factors mediated the relationship between the intervention and its psychological benefits, with self-efficacy accounting for 52% of the reduction in psychological distress. No significant differences in heart rhythm coherence were observed. This study highlights the critical role of self-efficacy and illness perceptions in enhancing psychological health in prostate cancer patients through the PC-PEP. The results underscore this program's effectiveness and the key mechanisms through which it operates. Given the high rates of distress among men undergoing prostate cancer treatments, these findings emphasize the importance of integrating the PC-PEP into clinical practice. The implementation of the PC-PEP in clinical settings can provide a structured approach to reducing psychological distress and improving overall patient well-being. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Addressing controversial areas in the management of advanced prostate cancer in Canada

Author

Saad, Fred, primary, Hotte, Sebastien J., additional, Noonan, Krista, additional, Malone, Shawn, additional, Morash, Christopher, additional, Niazi, Tamim, additional, Rendon, Ricardo A., additional, Shayegan, Bobby, additional, Basappa, Naveen S., additional, Cagiannos, Ilias, additional, Danielson, Brita, additional, Delouya, Guila, additional, Fernandes, Ricardo, additional, Ferrario, Cristiano, additional, Finelli, Antonio, additional, Gotto, Geoffrey T., additional, Hamilton, Robert J., additional, Izard, Jason P., additional, Kapoor, Anil, additional, Lalani, Aly-Khan, additional, Lavallée, Luke T., additional, Ong, Michael, additional, Pouliot, Frédéric, additional, So, Alan I., additional, Yip, Steven, additional, and Chi, Kim N., additional

Published
2023
Full Text
View/download PDF

28. PC-PEP, a Comprehensive Daily Six-Month Home-Based Patient Empowerment Program Leads to Weight Loss in Men with Prostate Cancer: A Secondary Analysis of a Clinical Trial.

Author

MacNevin, Wyatt, Ilie, Gabriela, Rendon, Ricardo, Mason, Ross, Spooner, Jesse, Chedrawe, Emily, Patil, Nikhilesh, Bowes, David, Bailly, Greg, Bell, David, Wilke, Derek, Zahavich, Jeffery B. L., MacDonald, Cody, and Rutledge, Robert David Harold

Subjects
PATIENT participation, PROSTATE cancer patients, WEIGHT loss, SECONDARY analysis, CLINICAL trials
Abstract

Background: The Prostate Cancer—Patient Empowerment Program (PC-PEP) is a six-month daily home-based program shown to improve mental health and urinary function. This secondary analysis explores weight loss in male PC-PEP participants. Methods: In a randomized clinical trial with 128 men undergoing curative prostate cancer (PC) treatment, 66 received 'early' PC-PEP, while 62 were assigned to the 'late' waitlist-control group, receiving 6 months of standard-of-care treatment followed by 6 months of PC-PEP. PC-PEP comprised 182 daily emails with video-based exercise and dietary (predominantly plant-based) education, live online events, and 30 min strength training routines (using body weight and elastic bands). Weight and height data were collected via online surveys (baseline, 6 months, and 12 months) including medical chart reviews. Adherence was tracked weekly. Results: No attrition or adverse events were reported. At 6 months, the early PC-PEP group experienced significant weight loss, averaging 2.7 kg (p < 0.001) compared to the waitlist-control group. Weight loss was noted in the late intervention group of PC-PEP, albeit less pronounced than in the early group. Early PC-PEP surgery patients lost on average 1.4 kg (SE = 0.65) from the trial's start to surgery day. High adherence to exercise and dietary recommendations was noted. Conclusions: PC-PEP led to significant weight loss in men undergoing curative prostate cancer treatment compared to standard-of-care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice.

Author

Chi, Kim N., Yip, Steven M., Bauman, Glenn, Probst, Stephan, Emmenegger, Urban, Kollmannsberger, Christian K., Martineau, Patrick, Niazi, Tamim, Pouliot, Frédéric, Rendon, Ricardo, Hotte, Sebastien J., Laidley, David T., and Saad, Fred

Subjects
CASTRATION-resistant prostate cancer, ANDROGEN receptors, ADVERSE health care events
Abstract

Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a therapeutic target. Lutetium-177 (177Lu)-PSMA-617 is the first radioligand therapy to be approved in Canada for use in patients with metastatic castration-resistant prostate cancer (mCRPC). As this treatment represents a new therapeutic class, guidance regarding how to integrate it into clinical practice is needed. This article aims to review the evidence from prospective phase 2 and 3 clinical trials and meta-analyses of observational studies on the use of 177Lu-PSMA-617 in prostate cancer and discuss how Canadian clinicians might best apply these data in practice. The selection of appropriate patients, the practicalities of treatment administration, including necessary facilities for treatment procedures, the assessment of treatment response, and the management of adverse events are considered. Survival benefits were observed in clinical trials of 177Lu-PSMA-617 in patients with progressive, PSMA-positive mCRPC who were pretreated with androgen receptor pathway inhibitors and taxanes, as well as in taxane-naïve patients. However, the results of ongoing trials are awaited to clarify questions regarding the optimal sequencing of 177Lu-PSMA-617 with other therapies, as well as the implications of predictive biomarkers, personalized dosimetry, and combinations with other therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Management, outcomes and predictors of recurrence in chromophobe renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).

Author

Arenovich, Erica, Breau, Rodney H., Mallick, Ranjeeta, Rendon, Ricardo A., Feifer, Andrew, Pouliot, Frederic, Tanguay, Simon, Lavallee, Luke, Lattouf, Jean-Baptiste, Nayak, Jasmir G., Bhindi, Bimal, Bansal, Rahul K., Finelli, Antonio, Mannas, Miles, Richard, Patrick O., Lalani, Aly-Khan A., Heng, Daniel Yick Chin, Bjarnason, Georg A., Basappa, Naveen S., and Wood, Lori

Published
2024
Full Text
View/download PDF

31. The impact of robotic surgery access on the management of patients with clinical stage I kidney tumors at Canadian academic centers

Author

Lemire, Francis, primary, Zhang, MengQi, additional, Anderson, Patrick, additional, Finelli, Antonio, additional, Rendon, Ricardo A., additional, Tanguay, Simon, additional, Bansal, Rahul, additional, Bhindi, Bimal, additional, So, Alan I., additional, Pouliot, Frédéric, additional, Dean, Lucas, additional, Mallick, Ranjeeta, additional, Lavallée, Luke T., additional, and Breau, Rodney H., additional

Published
2023
Full Text
View/download PDF

32. An Actionable Expert-System Algorithm to Support Nurse-Led Cancer Survivorship Care: Algorithm Development Study

Author

Pfisterer, Kaylen J, primary, Lohani, Raima, additional, Janes, Elizabeth, additional, Ng, Denise, additional, Wang, Dan, additional, Bryant-Lukosius, Denise, additional, Rendon, Ricardo, additional, Berlin, Alejandro, additional, Bender, Jacqueline, additional, Brown, Ian, additional, Feifer, Andrew, additional, Gotto, Geoffrey, additional, Saha, Shumit, additional, Cafazzo, Joseph A, additional, and Pham, Quynh, additional

Published
2023
Full Text
View/download PDF

33. 2023 Canadian Urological Association guideline: Genetic testing in prostate cancer

Author

Rendon, Ricardo A., primary, Selvarajah, Shamini, additional, Wyatt, Alexander W., additional, Kolinsky, Michael, additional, Schrader, Kasmintan A., additional, Fleshner, Neil E., additional, Kinnaird, Adam, additional, Merrimen, Jennifer, additional, Niazi, Tamim, additional, Saad, Fred, additional, Shayegan, Bobby, additional, Wood, Lori, additional, and Chi, Kim N., additional

Published
2023
Full Text
View/download PDF

34. Assessing the Efficacy of a 28-Day Comprehensive Online Prostate Cancer Patient Empowerment Program (PC-PEP) in Facilitating Engagement of Prostate Cancer Patients in Their Survivorship Care: A Qualitative Study

Author

Ilie, Gabriela, primary, MacDonald, Cody, additional, Richman, Hal, additional, Rendon, Ricardo, additional, Mason, Ross, additional, Nuyens, Alexandra, additional, Bailly, Greg, additional, Bell, David, additional, Patil, Nikhilesh, additional, Bowes, David, additional, Champion, Emmi, additional, Wilke, Derek, additional, Massoeurs, Lia, additional, Hassan, Nada, additional, and Rutledge, Robert David Harold, additional

Published
2023
Full Text
View/download PDF

35. Genetic testing practices among specialist physicians who treat prostate cancer

Author

Yip, Steven M., primary, Morash, Christopher, additional, Kolinsky, Michael P., additional, Kapoor, Anil, additional, Ong, Michael, additional, Selvarajah, Shamini, additional, Nuk, Jennifer, additional, Compton, Katie, additional, Pouliot, Frederic, additional, Lavallée, Luke T., additional, Khalaf, Daniel J., additional, Hamilton, Robert J., additional, Gotto, Geoffrey T., additional, Rendon, Ricardo A., additional, Antebi, Elie, additional, Hotte, Sebastien J., additional, Malone, Shawn, additional, Chi, Kim N., additional, Drachenberg, Darrel E., additional, Saad, Fred, additional, Chan, Jonathan, additional, Ferrario, Cristiano, additional, Ko, Jenny, additional, Shayegan, Bobby, additional, Parimi, Sunil, additional, So, Alan I., additional, Feifer, Andrew, additional, Jansz, Kenneth, additional, Finch, Daygen, additional, Chin, Joseph L., additional, Osborne, Brendan, additional, Ho, Kai Fai, additional, Demanga Galamo, Corine, additional, Zardan, Anousheh, additional, and Niazi, Tamim, additional

Published
2023
Full Text
View/download PDF

36. Estimated glomerular filtration rate from the renal hypothermia trial: clinical implications

Author

Lemire, Francis, primary, Fergusson, Dean A., additional, Knoll, Greg, additional, Morash, Christopher, additional, Lavallée, Luke T., additional, Mallick, Ranjeeta, additional, Finelli, Antonio, additional, Kapoor, Anil, additional, Pouliot, Frédéric, additional, Izawa, Jonathan, additional, Rendon, Ricardo, additional, Cagiannos, Ilias, additional, and Breau, Rodney H., additional

Published
2023
Full Text
View/download PDF

37. 2023 UPDATE – Canadian Urological Association guideline: Management of cystic renal lesions

Author

Richard, Patrick O., primary, Violette, Philippe D., additional, Bhindi, Bimal, additional, Breau, Rodney H., additional, Gratton, Matthieu, additional, Jewett, Michael A.S., additional, Kapoor, Anil, additional, Pouliot, Frederic, additional, Leveridge, Michael, additional, So, Alan I., additional, Whelan, Tom F., additional, Rendon, Ricardo A., additional, Tanguay, Simon, additional, and Finelli, Antonio, additional

Published
2023
Full Text
View/download PDF

39. Nurse-led virtual prostate cancer clinic for survivorship care: Qualitative study of healthcare professional experiences and needs

Author

Young, Karen, primary, Xiong, Ting, additional, Ng, Denise, additional, Jiao, Tina, additional, Lohani, Raima, additional, Pfisterer, Kaylen, additional, Nunn, Caitlin, additional, Bryant-Lukosius, Denise, additional, Rendon, Ricardo, additional, Berlin, Alejandro, additional, Bender, Jacqueline, additional, Brown, Ian, additional, Feifer, Andrew, additional, Gotto, Geoffrey, additional, Cafazzo, Joseph, additional, and Pham, Quynh, additional

Published
2023
Full Text
View/download PDF

40. Nurse-led virtual prostate cancer clinic for survivorship care: Qualitative study of patient experiences and needs

Author

Xiong, Ting, primary, Young, Karen, additional, Pfisterer, Kaylen, additional, Ng, Denise, additional, Lohani, Raima, additional, Jiao, Tina, additional, Nunn, Caitlin, additional, Bryant-Lukosius, Denise, additional, Rendon, Ricardo, additional, Berlin, Alejandro, additional, Bender, Jacqueline, additional, Brown, Ian, additional, Feifer, Andrew, additional, Gotto, Geoffrey, additional, Cafazzo, Joseph, additional, and Pham, Quynh, additional

Published
2023
Full Text
View/download PDF

41. Comparison of patients with renal cell carcinoma in adjuvant therapy trials to a real-world population

Author

Millan, Braden, primary, Breau, Rodney H., additional, Mallick, Ranjeeta, additional, Wood, Lori, additional, Rendon, Ricardo, additional, Finelli, Antonio, additional, So, Alan I., additional, Lavallée, Luke T., additional, Pouliot, Frédéric, additional, Bhindi, Bimal, additional, Heng, Daniel, additional, Drachenberg, Darrel, additional, Tanguay, Simon, additional, Dean, Lucas, additional, Basappa, Naveen S., additional, Lattouf, Jean-Baptiste, additional, Bjarnason, George, additional, Lalani, Aly-Khan, additional, and Kapoor, Anil, additional

Published
2023
Full Text
View/download PDF

42. An Examination of the Relationship between Mental Distress, Functional and Psychosocial Quality of Life Indicators in a Population Based Sample of Prostate Cancer Survivors Who Received Curative Treatment

Author

Ilie, Gabriela, MacDonald, Morgan, Bell, David, Rendon, Ricardo, Langille, Gavin, Bailly, Gregory, Mason, Ross, Bowes, David, Wilke, Derek, Patil, Nikhilesh, Lawen, Joseph, Grantmyre, John, Thompson, Robert, MacDonald, Cody, OʼMalley, Padraic, Pan, Larry, Bagnell, Scott, Campbell, Holly, Acker, Matthew, Massaro, Peter, Padmore, Dave, and Rutledge, Robert D. H.

Published
2020
Full Text
View/download PDF

43. 2023 UPDATE – Canadian Urological Association guideline: Management of cystic renal lesions: Prior to original publication (March 2017), this guideline underwent review by the CUA Guidelines Committee, CUA members at large, and the CUA Executive Board. The 2023 updates were app roved by the CUA Guidelines Committee and CUA Executive Board

Author

Richard, Patrick O., Violette, Philippe D., Bhindi, Bimal, Breau, Rodney H., Gratton, Matthieu, Jewett, Michael A.S., Kapoor, Anil, Pouliot, Frederic, Leveridge, Michael, So, Alan I., Whelan, Tom F., Rendon, Ricardo A., Tanguay, Simon, and Finelli, Antonio

Subjects
CUA guideline
Published
2023

45. Canadian Urological Association consensus guideline: Management of testicular germ cell cancer

Author

Hamilton, Robert J., Canil, Christina, Shrem, Noa Shani, Kuhathaas, Kopika, Jiang, Maria (Di), Chung, Peter, North, Scott, Czaykowski, Piotr, Hotte, Sebastien, Winquist, Eric, Kollmannsberger, Christian, Aprikian, Armen, Soulières, Denis, Tyldesley, Scott, So, Alan I., Power, Nicholas, Rendon, Ricardo A., O’Malley, Martin, Wood, Lori, and Jewett, Michael A.S.

Subjects
Oncology, Urology, CUA Guideline
Published
2022

46. MP32-11 FACTORS THAT PREDICT EARLY SALVAGE CYSTECTOMY POST-TRIMODAL THERAPY: RESULTS OF A MULTI-INSTITUTIONAL CANADIAN COHORT

Author

Macdonald, Landan, primary, Kool, Ronald, additional, Marcq, Gautier, additional, Kulkarni, Girish, additional, Breau, Rodney, additional, Shayegan, Bobby, additional, Kim, Michael, additional, Busca, Ionut, additional, Abdi, Hamidreza, additional, Uy, Michael, additional, Dawidek, Mark, additional, Fervaha, Gagan, additional, Cury, Fabio, additional, Alimohamed, Nimira, additional, Izawa, Jonathan, additional, Jeldres, Claudio, additional, Siemens, Robert, additional, Black, Peter, additional, Kassouf, Wassim, additional, and Rendon, Ricardo, additional

Published
2023
Full Text
View/download PDF

47. MP56-01 THE EFFECT OF DIFFERENT CONCURRENT CHEMOTHERAPY REGIMENS ON OUTCOMES IN PATIENTS TREATED WITH RADIATION FOR MUSCLE INVASIVE BLADDER CANCER

Author

Lemire, Francis, primary, Kool, Ronald, additional, Gautier, Marcq, additional, Siemens, Robert, additional, Shayegan, Bobby, additional, Kim, Michael, additional, Busca, Ionut, additional, Abdi, Hamidreza, additional, Dawidek, Mark, additional, Uy, Michael, additional, Fervaha, Gagan, additional, Cury, Fabio, additional, Alimohamed, Nimira, additional, Izawa, Jonathan, additional, Jeldres, Claudio, additional, Rendon, Ricardo, additional, Black, Peter, additional, Kulkarni, Girish, additional, Kassouf, Wassim, additional, and Breau, Rodney, additional

Published
2023
Full Text
View/download PDF

48. MP41-03 IS A RENAL TUMOUR BENIGN OR MALIGNANT? A PREDICTION TOOL INCLUDING PATIENTS MANAGED WITH SURGERY, ABLATION, OR SURVEILLANCE

Author

Nayak, Ameeta, primary, Lavallee, Luke, additional, Mallick, Ranjeeta, additional, Tanguay, Simon, additional, Pouliot, Frederic, additional, Finelli, Antonio, additional, Kapoor, Anil, additional, Rendon, Ricardo, additional, So, Alan, additional, Drachenberg, Darrel, additional, Bhindi, Bimal, additional, Lattouf, Jean-Baptiste, additional, Dean, Lucas, additional, Lalani, Aly-Khan, additional, Wood, Lori, additional, Heng, Daniel, additional, and Breau, Rodney, additional

Published
2023
Full Text
View/download PDF

49. PD09-02 THE IMPACT OF VARIANT HISTOLOGY ON CLINICAL OUTCOMES AFTER RADIATION-BASED THERAPY FOR MUSCLE-INVASIVE BLADDER CANCER

Author

Halstuch, Daniel, primary, Kool, Ronald, additional, Marcq, Gautier, additional, Breau, Rodney H, additional, Black, Peter C, additional, Shayegan, Bobby, additional, Kim, Michael, additional, Busca, Ionut, additional, Abdi, Hamidreza, additional, Dawidek, Mark T., additional, Uy, Michael, additional, Fervaha, Gagan, additional, Cury, Fabio L., additional, Alimohamed, Nimira S., additional, Jeldres, Claudio, additional, Rendon, Ricardo, additional, Siemens, D. Robert, additional, Kulkarni, Girish S., additional, Kassouf, Wassim, additional, and Izawa, Jonathan I., additional

Published
2023
Full Text
View/download PDF

50. MP63-01 AN INTERIM ANALYSIS OF A PHASE II CLINICAL STUDY OF INTRAVESICAL PHOTO DYNAMIC THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS)

Author

Kulkarni, Girish, primary, Richards, Kyle, additional, Black, Peter C., additional, Rendon, Ricardo, additional, Chin, Joseph, additional, Shore, Neal, additional, Jayram, Gautam, additional, Kramolowsky, Eugene, additional, Saltzstein, Daniel, additional, Agarwal, Piyush, additional, Belkoff, Laurence, additional, O'Donnell, Michael, additional, Kamat, Ashish M., additional, Zlotta, Alexandre, additional, Jewett, Michael A. S., additional, Lamm, Donald, additional, DeGruttola, Victor, additional, Mandel, Arkady, additional, Dumoulin-White, Roger J., additional, and Kassouf, Wassim, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results